is confirmed by the authors who used up to 3 ml of EVOH per patient and reported a total injection time of DMSO and Onyx Ò up to 45 minutes for their procedure. Procedural time often is of essence when used on an emergency basis, and the use of Onyx Ò may lead to a loss of precious time compared with other faster embolic agents, such as glue, in such a setting. Third, DMSO is volatile and is excreted via respiration and sweat. This has a typical smell, which may last a few days. The patient should be warned to expect this. Last, Onyx Ò is very expensive compared with other commonly used embolic materials, and its cost increases with higher concentrations of copolymer. Its high cost explains its restricted use in neuroradiology in most of the institutions around the world and needs to be borne in mind when used in other organs. In conclusion, we think that Onyx Ò is a very promising, but too luxurious, embolic agent at this time for its use in peripheral indications.
